Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Investor Presentation (May 2011)
22 slides from Inovio Pharmaceuticals's investor presentation, May 2011
Slide 1: A Phase II Developer of DNA Vaccines for Cancers and Infectious Diseases
A Phase II Developer of DNA Vaccines for Cancers and Infectious Diseases NYSE Amex: INO J. Joseph Kim, Ph.D. President & CEO Page 1
Slide 2: Forward Looking Statement
Forward Looking Statement Our commentary and responses to your questions may contain forward-looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Inovio’s tech
Slide 3: Investment Highlights
Investment Highlights • Differentiated DNA vaccine development platform • Novel DNA vaccine design: universal protection • Superior delivery using proprietary electroporation technology • Dominant IP position for next generation vaccines/devices • Achieving industry-leading potency and safety • Best
Slide 4: Market Profile: Vaccines and Immune Therapies
Market Profile: Vaccines and Immune Therapies • Vaccines: attractive, growing market • Under-treated or untreated disease targets • New market opportunities: first cancer therapeutic vaccine approved in 2010: Provenge® for prostate cancer Page 4
Slide 5: DNA Vaccine Advantages over Traditional Vaccines
DNA Vaccine Advantages over Traditional Vaccines • Potential to extend applicability/capability of live virus vaccines, with equivalent immune responses but improved safety profile • Could be used to prevent and treat • Faster development • Easier to manufacture & store Problem: Better delivery requ
Slide 6: Inovio's Optimized Electroporation Delivery
Inovio’s Optimized Electroporation Delivery • Efficient/effective: • 1000X increase in gene expression • 100X increase in immune responses • Achieving far stronger T-cell immune responses than viral vectors • No unwanted immune response • No residual carrier/vector causing toxicity • Safe and tolera
Slide 7: Inovio's SynCon Universal Vaccines
Inovio’s SynCon™ Universal Vaccines Immune responses more cross-reactive (universal) than those induced by single-strain vaccines Page 7
Slide 8: Inovio's Product Pipeline
Inovio’s Product Pipeline Page 8
Slide 9: VGX-3100: Cervical Dysplasia/Cancer
VGX-3100: Cervical Dysplasia/Cancer Market/Needs • Cervical cancer – 99% caused by human papillomavirus (HPV) • Gardasil & Cervarix: preventive only; far less than 100% uptake • Worldwide: Second leading cancer killer in women~500,000 new cases cervical cancer – 50% fatal Phase I: VGX-3100 Therapeut
Slide 10: Phase II Study Design for VGX-3100 (CIN2/3)
Phase II Study Design for VGX-3100 (CIN2/3) • Randomized, blinded study: VGX-3100 with intramuscular electroporation vs. placebo control • Patients: CIN2/3 (cervical dysplasia) + HPV16/18 (which cause 70% of cervical cancers) • 1˚endpoint: CIN 2/3 lesion clearance after 3 vaccinations • Powered to d
Slide 11: Leukemia DNA Vaccine: Phase II
Leukemia DNA Vaccine: Phase II Market/Needs • Leukemia 300,000+ new cases and 222,000 deaths worldwide each year • $3 billion spent in US each year Vaccine • Wilms’ Tumor gene 1 (WT1) w/o electroporation (EP) in humans for other cancers: modest CD8+ T-cell and measurable clinical responses • Leukemi
Slide 12: Hepatitis C Virus Therapeutic Vaccine: Phase II
Hepatitis C Virus Therapeutic Vaccine: Phase II • HCV DNA therapeutic vaccine CHRONVAC-C® delivered using Inovio’s electroporation system • Phase I data • Safe and well-tolerated • T-cell immune responses against HCV observed • Vaccination + subsequent SOC (interferon and ribavirin): • RVR (rapid vi
Slide 13: SynCon HIV DNA Vaccines
SynCon™ HIV DNA Vaccines Market/Needs • Worldwide: 40 million people infected with HIV • USA: 1 million infected; 60,000 new infections annually Competition • Vaxgen protein vaccine: no effect • Sanofi poxvirus vaccine: no effect • Merck adenovirus vaccine: no effect • Poxvirus prime + protein boost
Slide 14: Phase I PENNVAX-B HIV Vaccine Study
Phase I PENNVAX™- B HIV Vaccine Study • SynCon™ PENNVAX™-B DNA vaccine targets HIV gag, pol, and env (clade B) • Randomized, placebo-controlled Phase I study conducted by HVTN • 48 vaccinated subjects: • 8 subjects: placebo • 10 subjects:1 mg dose of PENNVAX™-B vaccine • 30 subjects:1 mg dose of PEN
Slide 15: Influenza: In Need of a New Paradigm
Influenza: In Need of a New Paradigm Market/Needs • $4 billion global market • Influenza viruses classified as sub-types, e.g. H1N1, H2N2, based on combinations of HA and NA proteins • H1, H2, H3: > 90% of all human flu infection; H5: avian flu, extremely lethal • Within subtypes, virus mutates extr
Slide 16: SynCon Universal Influenza Vaccines
SynCon™ Universal Influenza Vaccines • Target critical sub-types (box) Influenza A sub-types responsible for key seasonal & pandemic outbreaks of last century, • 100% protection in mice and plus lethal sub-type of potential concern (H5N1) ferrets against H5N1 & H1N1 challenge • Complete proof of con
Slide 17: Other Assets and Programs
Other Assets and Programs • Partnered Phase I study: hTERT cancer DNA vaccine • Merck conducting a Phase 1 clinical trial of a DNA cancer vaccine encoding hTERT using Inovio’s electroporation delivery system • Partial ownership VGX International Inc. (KSE:011000) • Majority ownership VGX Animal Heal
Slide 18: Experienced Management Team
Experienced Management Team J. Joseph Kim, Ph.D., President & Chief Executive Officer • 19+ years biotechnology/pharma management; 9 years at Merck; hepatitis A and B vaccines manufacturing; HIV vaccine (Ad5) R&D; 100+ publications on DNA vaccines; Wharton MBA (Finance); co-founded VGX Pharmaceutica
Slide 19: Premier Advisors
Premier Advisors Scientific Advisory Board David B. Weiner, Ph.D. • Professor, Dept. of Pathology & Laboratory Medicine, U of Pennsylvania • “Father of DNA vaccines” – pioneer Iacob Mathiesen, Dr. Philos. • International electroporation technology expert Stanley A. Plotkin, M.D. • Emeritus Professor
Slide 20: Financial Information
Financial Information Financial Position Cash & short term investments (Dec. 31, 2010) $21.8 M Financing (Jan. 27, 2011: $24.3M gross) ~ $23 M Debt 0 M Cash runway YE 2013 Shares (NYSE Amex: INO) Issued & outstanding (Feb. 24, 2011) 127.3 M Page 20
Slide 21: Catalysts
Catalysts Done Timing Program Milestone Q1 2011 Leukemia (University of Launch Phase II Southampton) Q1 VGX-3100 cervical cancer Launch Phase II Q1 HCV therapeutic vaccine Launch Phase II (ChronTech Pharma) Q2 INO-3510: H1N1+H5N1 Launch phase I (intradermal delivery) Q2/3 VGX-3400X: H5N1 Phase
Slide 22: Inovio Pharmaceuticals
Inovio Pharmaceuticals Developing the next generation of vaccines to prevent and treat cancers and infectious diseases [email protected] NYSE Amex: INO Page 22
Inovio Pharmaceuticals — Investor Presentation (May 2011) on 6ix